Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarting Cerezyme - For the Public

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Contact: Marketed Health Products Directorate (MHPD)

The Health Products and Food Branch (HPFB) posts on the Health Canada Web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.

This is duplicated text of a letter from Genzyme Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Public Communication
Health Canada Endorsed Important Safety Information on Cerezyme (imiglucerase for injection)

December 21, 2009

Subject: Cerezyme^® (imiglucerase for injection) Supply and Recommendations for Restarting Cerezyme

Cerezyme is used to treat patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease resulting in one or more of the following conditions:

• anaemia
• low platelet count
• bone disease
• enlarged liver or spleen

As a result of an interruption in production, Genzyme Canada advised the Canadian Gaucher community on June 29, 2009 of a treatment guidance designed to conserve the supply of Cerezyme in order to protect the most vulnerable patients. This guidance was established by the international Cerezyme Stakeholders Working Group (a group of Gaucher community stakeholders including medical experts and patient advocates).

In January 2010, Genzyme Canada will begin shipping Cerezyme to all Canadian patients who have had to stop receiving their Cerezyme treatment. Genzyme will fulfill orders one infusion at a time for each patient. Healthcare providers have been informed of this and provided with recommendations for resuming treatment. Patients should contact their doctors to arrange to restart treatment in 2010. Your doctor should determine how and where to restart Cerezyme based on your present condition and how you have tolerated Cerezyme^® infusions in the past. For some patients with a history of infusion reactions, this may imply restarting Cerezyme in a hospital or clinic setting.

Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious reactions related to restarting infusions of CEREZYME or other serious or unexpected adverse reactions in patients receiving CEREZYME should be reported to Genzyme Canada Inc. or Health Canada at the following addresses:

For any additional information, please contact Genzyme Medical Information at 1-800-745-4447 or medinfo@genzyme.com.

Sincerely,

original signed by

Brian Lewis
General Manager
Genzyme Canada Inc.